Convection-enhanced delivery of ¹³¹I-chTNT-1/B mAB for treatment of high-grade adult gliomas

Bibliography

• Central Brain Tumor Registry of the United States. Hinsdale, IL: 2010. Available from: http://www.cbtrus.org/factsheet/factsheet.html [Last accessed 6 March 2011]
   Google Scholar
• Ashby LS, Ryken TC. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus 2006;20(E3):1-13
   Google Scholar
• Walker MD, Alexander E Jr, Hunt WE Evaluation of BCNU and/or Radiotherapy in the treatment of anaplasticgliomas: a cooperative clinical trial. J Neurosurg 1978;49:333-43
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110
   PubMed Web of Science ®Google Scholar
• Jagannathan J, Prevedello DM, Dumont AS, Laws ER. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme. Neurosurg Focus 2006;20(E8):1-8
   Google Scholar
• Chamberlain MC. Treatment options for glioblastoma. Neurosurg Focus 2006;20(E19):1-9
   Google Scholar
• Stummer W, Novotney A, Stepp H, Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid–induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000;93:1003-13
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010;116:3988-99
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm S, Chamberlain MC, A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010;116:5297-305
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, Nghiemphu PL, Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29:142-8
   PubMed Web of Science ®Google Scholar
• Brem H, Piatadosi S, Burger PC, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-12
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD, Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583-8
   PubMed Web of Science ®Google Scholar
• Bobo RH, Laske DW, Akbasak A, Convection-enhanced delivery of macromolecules into the brain. Proc Natl Acad Sci U S A 1994;91:2076-80
   PubMed Web of Science ®Google Scholar
• Laske DW, Morrison PF, Lieberman DM, Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomorgraphy imaging. J Neurosurg 1997;87:586-94
   PubMed Web of Science ®Google Scholar
• Groothius DR, Sherman W, Itskovich AC, Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 1999;90:321-31
   PubMed Web of Science ®Google Scholar
• Chen MY, Russell RL, Morrison PF, Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999;90:315-20
   PubMed Web of Science ®Google Scholar
• Lidar Z, Mardor Y, Jonas T, Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study. J Neurosurg 2004;100:472-9
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE, Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008;10:320-9
   PubMed Web of Science ®Google Scholar
• Weber F, Asher A, Bucholz R, Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003;64:125-37
   PubMed Web of Science ®Google Scholar
• Kunwar S, Chang S, Westphal M, Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010;12:871-81
   PubMed Web of Science ®Google Scholar
• Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8
   PubMed Web of Science ®Google Scholar
• Bigner DD, Brown MT, Friedman AH, Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998;16:2202-12
   PubMed Web of Science ®Google Scholar
• Akabani G, Reardon DA, Coleman RE, Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81c6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 2005;46:1042-51
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Carpenter SP, Roberts K, Shan JS. 131I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin Biol Ther 2006;6:539-45
   PubMed Web of Science ®Google Scholar
• Cotara® Oncology. Tustin, CA: Peregrine Pharmaceuticals, Inc., 2003-2011. Available from: http://www.peregrineinc.com/pipeline/cotara-oncology.html [Last accessed 6 March 2011]
   Google Scholar
• Patel SJ, Shapiro WR, Laske DW, Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005;56:1243-52
   PubMed Web of Science ®Google Scholar
• Khawli LA, Mizokami MM, Sharifi J, Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm 2002;17:359-70
   PubMed Web of Science ®Google Scholar
• Street HH, Goris ML, Fisher GA, Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm 2006;21:243-56
   PubMed Web of Science ®Google Scholar
• Peregrine Pharmaceuticals. Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse. ClinicalTrials.gov NCT00677716. Available from: http://clinicaltrials.gov/ct2/show/NCT00677716?term=cotara&rank=1. [Last accessed6 March 2011]
   Google Scholar
• Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 2009;9:1087-98
   PubMed Web of Science ®Google Scholar
• Boskovitz A, Wikstrand CJ, Kuan CT, Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther 2004;4:1453-71
   PubMed Web of Science ®Google Scholar
• Zalutsky MR, Reardon DA, Akabani G, Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008;49:30-8
   PubMed Web of Science ®Google Scholar
• Reardon DA, Zalutsky MR, Akabani G, A pilot study 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 2008;10:182-9
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA, Sampson JH, Kunwar S, Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results. Neurosurgery 2007;61:1031-7; discussion 1037 – 1038
   PubMed Web of Science ®Google Scholar
• Vredenbergh JJ, Desjardins A, Herndon JE II, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4472-9
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487-94.
   PubMed Web of Science ®Google Scholar